First oral thrombin inhibitor reaches market
AstraZeneca's anticoagulant Exanta (ximelagatran) has been launched in Germany, its first market worldwide, for the prevention of blood clots in patients undergoing hip or knee replacement surgery.
Archives for June 24, 2004
Merck backs new cancer drug in $350m deal
A strong indicator of the potential of a new type of drug to treat cancer - the Aurora kinase inhibitors - has come with Merck & Co's decision to invest up to $350 million (€288m) in a license for the lead compound in the class, reports Phil Taylor.
Discovery heralds better adjuvants
Adjuvants - substances that are added to vaccines to intensify the immune response to an antigen which have been used for over 80 years - are beginning to be understood by researchers who believe more effective adjuvants can be designed.